Keyphrases
MYC Translocation
61%
Large B-cell Lymphoma
59%
Double Hit
50%
Diffuse Large B-cell Lymphoma (DLBCL)
48%
B-cell Lymphoma 2 (Bcl-2)
41%
BCL2 Translocation
30%
Hematopathologist
28%
Young Patients
28%
Myeloproliferative Neoplasms
28%
PD-L1 Expression
28%
High Risk
28%
R-CHOP
25%
BCL6
24%
Translocation Partner Genes
22%
Programmed Death-ligand 1 (PD-L1)
22%
Translocated
19%
Etoposide
18%
Prognostic Impact
17%
Cell of Origin
16%
R-CHOP Chemotherapy
16%
Clinical Data
16%
Poor Outcome
16%
Chemotherapy
15%
Fluorescence in Situ Hybridization
14%
MYC Expression
14%
Single-center Experience
14%
CHOEP
14%
Rotator Cuff Repair
14%
Functional Resonance
14%
B Cells
14%
WHO Classification
14%
Copy number Variation
14%
Learning Effect
14%
Non-inflamed
14%
Clinical Correlation
14%
World Health Organization
14%
Tendon
14%
CD68
14%
High-grade B-cell Lymphoma
14%
Outcome Prediction
14%
Magnetic Resonance Imaging
14%
Tumor-associated Macrophages
14%
Topoisomerase
14%
Patient Survival
14%
Prognostic Biomarker
14%
Image Evaluation
14%
Bone Marrow Biopsy
13%
MYC Protein
12%
Protein Expression
12%
Clinical Diagnosis
11%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
51%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
33%
B Cell
29%
Myeloproliferative Neoplasm
28%
Large-Cell Lymphoma
28%
Etoposide
17%
Overall Survival
17%
Germinal Center
15%
Reproducibility
14%
Rotator Cuff
14%
Magnetic Resonance Imaging
14%
Biological Marker
14%
Topoisomerase
14%
Morphology
14%
Progression Free Survival
13%
Bone Marrow Biopsy
13%
Fluorescence in Situ Hybridization
11%
Diagnosis
11%
Drug Delivery System
10%
Protein Expression
9%
Rituximab
8%
Histology
7%
Clinical Finding
7%
Clinician
7%
Gene Mutation
6%
Chromosome 20
6%
Gene Dosage
6%
Chromosome 17
6%
Vincristine
5%
Prednisone
5%
Cyclophosphamide
5%
Doxorubicin
5%
Chemotherapy Regimens
5%
Immunoglobulin
5%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
PD-L1
28%
BCL6
21%
Topoisomerase
14%
DNA Topoisomerase
14%
Tumor-Associated Macrophage
14%
Overall Survival
13%
Progression Free Survival
12%
Drug Targeting
10%
Intravenous Immunoglobulin
9%
Protein Expression
9%
Fluorescence in Situ Hybridization
8%
CD68
7%
Protein Expression Level
7%
Rituximab
7%
Gene Dosage
6%
Chromosome 20
6%
TOP1
6%
Gene Mutation
6%
Polysomy
6%
Chromosome 17
6%
TOP2A
6%
Genetics
5%
CD163
5%
